Richard Jack PhD

Richard Jack, PhD, has more than 15 years of drug discovery research and development experience in the biotechnology and pharmaceutical companies. Most recently, he led the research efforts at Madera Biosciences, a company developing small molecules for the clearance of amyloid β in neurodegenerative diseases. Prior to joining Madera, he was Vice President of Research for Tanabe Research Labs-USA (TRL), the US discovery arm of Mitsubishi-Tanabe Pharma.

While there, he and his team advanced multiple small molecule programs to development. Prior to his tenure at TRL, Dr. Jack was a scientific cofounder and Vice President, Biology at Triad Therapeutics, a structure-based drug discovery company that developed a leading kinase inhibitor program that was licensed to Novartis and advanced into human clinical trials. He began his biopharmaceutical career at La Jolla Pharmaceutical, where he developed and advanced preclinical and clinical biologics programs for antibody-mediated diseases.